Page 112 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman
P. 112

Chapter 5
16. Gage JC, Katki HA, Schiffman M, et al. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathol. 2014 Nov;122(11):842-50.
17. Guarisi R, Sarian LO, Hammes LS, et al. Smoking worsens the prognosis of mild abnormalities in cervical cytology. Acta Obstet Gynecol Scand. 2009;88(5):514-20.
18. de Mello Silva MV, Coutinho IC, de Andrade Heraclio S, Fittipaldi HM, Jr., Katz L. Factors associated with the persistence/recurrence of CIN2/3 in women submitted to loop electrosurgical excision procedure in a teaching hospital in northeastern Brazil: a case- control study. J Low Genit Tract Dis. 2014 Oct;18(4):286-90.
19. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011 Aug;27(8):597-604.
20. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996 Dec;49(12):1373-9.
21. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical
intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009 Jan;113(1):18-25.
22. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006 Oct;59(10):1087-91. 23. Ho GY, Einstein MH, Romney SL, et al. Risk factors for persistent cervical intraepithelial neoplasia
grades 1 and 2: managed by watchful waiting. J Low Genit Tract Dis. 2011 Oct;15(4):268-75.
24. Discacciati MG, de Souza CA, d’Otavianno MG, et al. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur J Obstet
Gynecol Reprod Biol. 2011 Apr;155(2):204-8.
25. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic
changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014 Jun;14(6):395-
405.
26. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk
and high-risk early CIN lesions: role of markers of proliferative activity and differentiation
and Rb availability. Int J Gynecol Pathol. 2004 Apr;23(2):100-9.
27. Ovestad IT, Gudlaugsson E, Skaland I, et al. The impact of epithelial biomarkers, local immune
response and human papillomavirus genotype in the regression of cervical intraepithelial
neoplasia grades 2-3. J Clin Pathol. 2011 Apr;64(4):303-7.
28. Schiffman M, Boyle S, Raine-Bennett T, et al. The Role of Human Papillomavirus Genotyping
in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer
Epidemiol Biomarkers Prev. 2015 Sep;24(9):1304-10.
29. Schoorel EN, van Kuijk SM, Melman S, et al. Vaginal birth after a caesarean section: the
development of a Western European population-based prediction model for deliveries at
term. BJOG. 2014 Jan;121(2):194-201
30. Vergeldt TF, van Kuijk SM, Notten KJ, Kluivers KB, Weemhoff M. Anatomical Cystocele
Recurrence: Development and Internal Validation of a Prediction Model. Obstet Gynecol.
2016 Feb;127(2):341-7.
31. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid
110



































































   110   111   112   113   114